The TAMARACK study uses a test drug that is an Anti-body Drug Conjugate, or ADC, as a potential treatment option for metastatic castrate resistant prostate cancer. An ADC is an antibody with an anti-cancer drug attached. The antibody portion of the ADC brings the anti-cancer drug specifically to the cancer cell, where it will attach to a protein on the outside of the cancer cell. It causes damage leading to the death of the cancer cell. The antibody is specifically targeted to enter cancer cells.
The study compares two dose levels of the test drug and evaluates effectiveness and side effects.
If your prostate cancer is worsening, you may be eligible.